
# Development and validation of ensemble machine-learning based web-embedded decision supporting tool for prostate biopsy



AUA-2020

Jungyo Suh<sup>1</sup>, Sangjun Yoo<sup>2</sup>, Juhyun Park<sup>2</sup>, Sung Yong Cho<sup>1</sup>, Min Chul Cho<sup>2</sup>, Hwancheol Son<sup>2</sup>, Hyeon Jeong<sup>2</sup>






1. Department of Urology, Seoul National University hospital college of medicine 2. Department of Urology, SMG-SNU Boramae Medical Center

## INTRODUCTION

- There are several multivariable prediction models for diagnosing prostate cancer (PC) and clinically significant prostate cancer (csPC) none of them exhibit outstanding performance than PSA alone.
- Complex machine learning model makes better prediction with reflect complexity of real-world correlation of features.
- However, complex machine learning model has problem in black-box phenomena for clinical application.
- In this study, we developed and validated the explainable artificial intelligence (XAI) machine model (XGBoost) for calculating the probability of PC and csPC and deployed it using a webembedded structure for clinician's decision support prior to prostate biopsy.

# MATERIALS & METHODS


### Overall workflow



# Patients information

- **3832 prostate biopsy patients' database**
- Since March 2009 to October 2019
- ❖ Included parameters on DB: Age, Biopsy history, BMI, PSA level, free PSA level, Testosterone level, serum creatinine level, DRE abnormality, total prostate volume, transitional zone prostate volume, hypoechoic lesion on ultrasound

#### Feature selection



- Lesser parameter makes better application
- We reduced parameters using LASSO (least absolute shrinkage and selection operator) regression for each models


Model 1

for prostate cancer


probability

Model 2

#### Missing Value Imputation




#### Model Development



 Observations Uncertain area

for clinically significant prostate cancer probability


### Model Validation



#### RESULTS


#### Model 1 Performance

Parameters (8): Age, PSA, free PSA, Testosterone, Total volume prostate, transitional zone volume prostate, hypoechoic lesion, Previous number of prostate biopsy




#### Model 2 Performance


Parameters (7): Age, PSA, free PSA, Testosterone, Total volume prostate, transitional zone volume prostate, hypoechoic lesion



#### Sub-group analysis

# Model Deployment Hypoechoic lesion on TRUS:





#### Conclusion

- We successfully developed and validated a decision-supporting tool using XAI for calculating the probability of PC and csPC prior to prostate biopsy.
- You can access freely with <a href="URL: https://boramae-pcrc.appspot.com">URL: https://boramae-pcrc.appspot.com</a>